Please assess the completion status of the following clinical trial:

Trial Title: COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years old~* Infection with COVID-19 diagnosed with RT-PCR SARS-CoV-2 or withCT-scan of the chest suggesting viral pneumonia of peripheral predominance in a clinically relevant context~* Patient seen in hospitalization or consultation or in nursing home~* Diagnosed within the preceding 3 days~* Having at least one of the following two risk factors for complications:~  * age ≥75 years~ * Peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg~* Patients affiliated with or benefitting from a social security scheme~* Written and signed consent of the patient or a relative or legal representative or, if not possible, emergency inclusion procedure~Exclusion Criteria:~* Organ failure requiring admission to a resuscitation or high dependency unit~* Comorbidity that is life-threatening in the short-term (life expectancy \<3 months)~* Any reason that makes follow-up at day 28 impossible~* Vitamin D supplementation in the previous month, with the exception of treatment providing less than 800 IU of vitamin D per day~* Contraindication for vitamin D supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis D or hypercalcemia, known intolerance to vitamin D~* Participation in another simultaneous trial~* Safeguard of justice~* Peripheral capillary oxygen saturation (SpO2) ≤92% in spite of an oxygen therapy \> 5L/min

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): High dose of vitamin D3
- Comparator group (Type: ACTIVE_COMPARATOR): Standard dose of vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).